About Radyus

We’re a team of experienced drug developers with pharma R&D and venture capital backgrounds. We know what good looks like to buyers and investors when developing a new drug. Our services are designed to guide our clients to success and expedite drug development.

We work with biotech companies, academic startups, and venture capital firms.

Most frequently we partner with our clients at a lead optimization and candidate selection stage, through IND-enabling studies and into first in human trials.

Our expertise is in immunology, oncology, infectious diseases, metabolic diseases, and neurosciences - across modalities.

Our Team

  • Marta New, PhD, MBA

    Chief Executive Officer

  • Anthony Chilton, PhD

    Chief Operating Officer

  • Eric Springman, PhD

    Head of Development

  • David Ford, PhD, PMP

    Sr. Director, PM

  • Jen Schireiber, PhD, PMP

    Sr. BD Lead

  • Abigail (Abby) Cannon, PhD

    Project Lead

  • Alan Benjamin Frey, PhD

    Scientific Development

  • Dave Edwards, CBIOL, MRSB

    Toxicology Lead

  • Caitlin J. Couch (Risener), Phd

    Operations Manager

  • Lucy Outtrim, PhD Candidate

    Research Associate

Board of Directors

Scientific Advisory Board

  • Dennis Liotta, PhD

    Anti-Infectives

  • Mark Shlomchik, MD, PhD

    Immunology

  • Laura Soucek, PhD

    Oncology

  • Richard B. Silverman, PhD

    CNS/Neuro

  • Frederick (Rick) Sax, MD

    Cardiometabolic

Industry Advisory Board

  • Eric Rowinsky, MD

    Clinical Development

  • John M. Sall, PharmD, PhD

    Regulatory Strategy

  • Sasha Khursheed Said, BA

    Sales Strategy

  • Anne Horgan, PhD

    Venture Capital

  • Ted B. Leggett, MS

    Quality

  • Russell B. Allen, BA

    Commercialization

  • David Day, BA

    University Relations and Licensing

  • Priyanka Rohatgi, PhD

    Venture Capital & Business Development